Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BIO2018

Roche's Perjeta pertuzumab

NICE backs Roche’s Perjeta for routine NHS use

Set to become first new breast cancer drug in nine years after discount agreed

- PMLiVE

The rise and rise of Generation Now

Investigating the positive changes millennials are bringing to healthcare

- PMLiVE

NICE backs expanded use of Brilique in final guidance

AZ’s maintenance therapy recommended for long-term use, post-heart attack

- PMLiVE

NICE backs Eisai’s Halaven for breast cancer

Reverses 2012 rejection due to new data and patient access discount

- PMLiVE

NICE set to reject Merck’s Erbitux for head and neck cancer

Draft guidance rules the treatment does not provide value for money

Communicating with payers to improve patient access

A transforming NHS brings with it many opportunities. Working with payers to put patients at the heart of everything while reducing costs is fundamental to success.

- PMLiVE

UK to cut wait to innovative treatments by four years

Proposals in the Accelerated Access Review aim to speed up access to innovation

- PMLiVE

NHS marks its Twitter debut with story-sharing initiative

Three-month project will see a patient or staff member take over the new account

- PMLiVE

Regional NHS pulmonary rehabilitation video campaign launched

Aims to boost referral rates among GPs in the north east of England

- PMLiVE

The UK’s new Cancer Drugs Fund

"Clearer, faster decision-making" promised

UK to establish a digital academy for healthcare professionals

NHS technology plans will also see 12 trusts act as digitisation pioneers

- PMLiVE

NHS promotes person-centred care in new dementia film

Highlights the importance of enabling people to live well with the condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links